Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-communicable Disease Clear all

Conditions: Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions: Esophageal cooling/warming device, Mild hypothermia, Normothermia; Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Aurora, Colorado • Houston, Texas

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 12 more

Conditions: Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis, Candidiasis, Aspergillosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 12,032 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: HIV Infections
Interventions: Nevirapine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Ridgefield, Connecticut

Conditions: Indolent Non-Hodgkin's Lymphoma
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, HIV Infections
Interventions: Peginterferon alfa-2b, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sepsis, Non-Infectious Systemic Inflammatory Response Syndrome
Interventions: SeptiCyte (various); Diagnostic Test
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Month to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Ventilator Associated Pneumonia (VAP)
Interventions: molecular analysis of exhaled breath condensate, molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate, molecular analysis of bronchoalveolar lavage (BAL) aspirate; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Infectious Disease
Interventions: Nozin® Nasal Sanitizer®, Placebo; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: HIV Seropositivity, Adherence, Medication
Interventions: MI sessions, TMQQ, Type of compensation; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-infectious Intermediate and Posterior Uveitis
Interventions: Daclizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Zika Virus
Interventions: mRNA-1325, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: San Diego, California • Melbourne, Florida • Peoria, Illinois

Conditions: Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Non Hodgkin Lymphoma, Hemophagocytic Lymphohistiocytosis, Familial Hemophagocytic Lymphohistiocytosis, Hemophagocytic Syndrome, Epstein Barr Virus Infection, X-linked Lymphoproliferative Disease
Interventions: iCaspase9-transduced T cells, AP1903; Biological · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2029
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Medication Adherence
Interventions: MedViewer report; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Seropositivity
Interventions: Placebo, Rouvastatin calcium; Drug
Lead sponsor: Alison Morris; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • Pittsburgh, Pennsylvania

Conditions: Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone; Device · Drug
Lead sponsor: Diane George; Other
Eligibility: Up to 22 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-healing Wound, Non-healing Diabetic Foot Ulcer, Diabetic Foot Infection
Interventions: TTAX01, Surgical resection and debridement, Systemic antibiotics, Off-loading; Biological · Procedure · Drug + 1 more
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 11
States / cities: Phoenix, Arizona • Sylmar, California • Miami, Florida + 8 more

Conditions: Hepatitis B
Interventions: EDP-514, Itraconazole, Carbamazepin, Quinidine; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: HIV Infections
Interventions: Atazanavir, Nelfinavir mesylate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 47
States / cities: Little Rock, Arkansas • Berkeley, California • Fountain Valley, California + 37 more

Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Interventions: Filgrastim, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Cytarabine, Dexamethasone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Uveitis, Posterior Uveitis, Panuveitis
Interventions: AEB071; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more

Conditions: Nontuberculous Mycobacterium Infection
Interventions: gNO; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Portland, Oregon • Charleston, South Carolina

Conditions: Clostridium Difficile
Interventions: Stool specimen; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 99 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Risk Reduction, HIV, Sexually Transmitted Infections (Not HIV or Hepatitis)
Interventions: Sex Pro mobile Application; Behavioral
Lead sponsor: Public Health Foundation Enterprises, Inc.; Other
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Prospective Observational Study on the Incidence of Opportunistic Fungal Infections

An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

Gene Expression Objective Definition of Early Sepsis In Children

Serial, Non-invasive Analysis of Exhaled Breath Condensate in Ventilated Trauma Patients

Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic

Supporting Health Behavior Among Persons Living With HIV Using Tech, MOST, and Behavioral Economics

Combination Daclizumab/Denileukin Diftitox to Treat Uveitis

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

Administration of Donor T Cells With the Caspase-9 Suicide Gene

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence (ENLIGHTEN)

Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)

Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma

Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics

Personalized HIV and STI Testing Tool